X4 Pharmaceuticals, Inc.
XFOR
$3.57
$0.071.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 346.33% | -90.60% | 79.08% | 215.18% | 250.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 346.33% | -90.60% | 79.08% | 215.18% | 250.44% |
| Cost of Revenue | 396.01% | -87.32% | 20.53% | 54.63% | 21.64% |
| Gross Profit | 336.49% | -91.24% | 94.70% | 324.62% | 458.31% |
| SG&A Expenses | -10.77% | -53.87% | -51.26% | -47.73% | -28.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.66% | -39.93% | -28.75% | -30.48% | -18.15% |
| Operating Income | 37.52% | -114.65% | 33.08% | 34.47% | 22.61% |
| Income Before Tax | 37.15% | -6,505.38% | 39.53% | 18.64% | -128.29% |
| Income Tax Expenses | -94.59% | -- | -100.00% | -300.00% | 105.56% |
| Earnings from Continuing Operations | 37.23% | -7,277.66% | 39.92% | 18.75% | -128.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.23% | -7,277.66% | 39.92% | 18.75% | -128.34% |
| EBIT | 37.52% | -114.65% | 33.08% | 34.47% | 22.61% |
| EBITDA | 40.51% | -123.55% | 33.20% | 34.61% | 23.22% |
| EPS Basic | 96.32% | -489.08% | 92.68% | 87.43% | -125.54% |
| Normalized Basic EPS | 96.31% | -446.02% | 92.57% | 89.48% | -63.73% |
| EPS Diluted | 96.26% | -500.75% | 92.66% | 87.41% | -125.59% |
| Normalized Diluted EPS | 96.31% | -447.22% | 92.57% | 89.48% | -64.03% |
| Average Basic Shares Outstanding | 1,604.36% | 1,746.33% | 1,547.49% | 546.30% | 10.95% |
| Average Diluted Shares Outstanding | 1,604.36% | 1,738.50% | 1,547.49% | 546.30% | 10.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |